3.07
-0.08(-2.54%)
Currency In USD
| Previous Close | 3.15 |
| Open | 3.1 |
| Day High | 3.13 |
| Day Low | 3.06 |
| 52-Week High | 4.97 |
| 52-Week Low | 1.75 |
| Volume | 64,563 |
| Average Volume | 80,154 |
| Market Cap | 42.45M |
| PE | -4.04 |
| EPS | -0.76 |
| Moving Average 50 Days | 3.15 |
| Moving Average 200 Days | 3.08 |
| Change | -0.08 |
If you invested $1000 in Grace Therapeutics, Inc. (GRCE) since IPO date, it would be worth $1,019.93 as of September 16, 2025 at a share price of $3.07. Whereas If you bought $1000 worth of Grace Therapeutics, Inc. (GRCE) shares 0 years ago, it would be worth $1,019.93 as of September 16, 2025 at a share price of $3.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trig